Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.

Education

Manufacturing

Pharmaceutical

Therapeutics

Vigil Neuro

Ivana Magovčević-Liebisch

Rizwan Manzer

Alysia Martins

Michael Cohen

Leah Gibson

Clarissa Martinez-Rubio

Donald McLaren

Jordan Jara

Julia Keefe

Shannon Ryan

Heidi Mizenko

Meghan Pagliarini

Anadina Garcia

David Gray

Cynthia Cassandro

Evangelia Hatzis

Kevin Durfee

Andreas Meier

Evan Thackaberry

Jennifer Ziolkowski

Jessica Stromme

Jonathan Houze

Elizabeth Thompson

Berkley Lynch

Dwayne Stanley

Liyue Huang

Jane Lydon

Borislav Dejanovic

Sharon Morani

Craig Bodycombe

Christian Mirescu

Weeteck Yeo

Research and Development

Leadership Team

Clinical Operations and Research

Finance and Accounting

Medical and Scientific Roles

Corporate Support Functions

Legal and Compliance

Teams at Vigil Neuro

Research and Development

Leadership Team

Clinical Operations and Research

Research and Development

Finance and Accounting

Medical and Scientific Roles

Corporate Support Functions

Legal and Compliance